Home › Funds › DAFNA Capital Management LLC › RNA
DAFNA Capital Management LLC position in RNA
ATRIUM THERAPEUTICS INC · Health Care
DAFNA Capital Management LLC reported holding 300,076 shares of RNA (ATRIUM THERAPEUTICS INC) in its Q3 2026 13F filing — a position valued at US$2.5M, representing 0.53% of its reported portfolio and ranking #38 among its reported holdings. DAFNA Capital Management LLC has disclosed RNA holdings in 2 of the last 2 reported quarters, going back to Q2 2026.
Last updated: 2026-11-17 · Source: SEC EDGAR Form 13F-HR
How DAFNA Capital Management LLC's RNA position evolved
DAFNA Capital Management LLC first disclosed a stake in RNA in Q2 2026 at 128,000 shares (US$1.7M). The position peaked in Q3 2026 at 300,076 shares, worth US$2.5M. Across 2 filings, DAFNA Capital Management LLC increased the stake 1 time(s), trimmed it 0 time(s) and left it unchanged 0 time(s). The most recent filing (Q3 2026) shows 300,076 shares valued at US$2.5M — an increase of 172,076 shares quarter over quarter.. Notable position changes include a 134% increase in Q3 2026 (shares fell 22% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q2 2026 | 128.00K | $1.72M | New |
| Q3 2026 | 300.08K | $2.48M | Add |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About RNA and 13F data
RNA (ATRIUM THERAPEUTICS INC) is a Health Care company. 79 other funds we track also report a position in RNA — the largest reported positions include Sessa Capital IM, L.P. (US$12.4M), O'Connor Alternative Investments LLC (US$4.6M), Bracebridge Capital, LLC (US$4.3M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding RNA
- Sessa Capital IM, L.P. 1.50M sh · $12.42M · Q3 2026
- O'Connor Alternative Investments LLC 559.14K sh · $4.63M · Q3 2026
- Bracebridge Capital, LLC 524.48K sh · $4.34M · Q3 2026
- TIG Advisors, LLC 506.93K sh · $4.20M · Q3 2026
- Arbiter Partners Capital Management LLC 311.72K sh · $2.58M · Q3 2026
- Kalehua Capital Management LLC 112.65K sh · $932.76K · Q3 2026
- Athos Capital Ltd 107.97K sh · $894.00K · Q3 2026
- Marble Bar Asset Management LLP 103.90K sh · $860.27K · Q3 2026
- Trium Capital LLP 58.38K sh · $483.40K · Q3 2026
- ALETHEA CAPITAL MANAGEMENT, LLC 43.76K sh · $362.32K · Q3 2026
- Slotnik Capital, LLC 39.93K sh · $330.62K · Q3 2026
- Fortress Investment Group LLC 20.00K sh · $165.60K · Q3 2026
More on DAFNA Capital Management LLC
FAQ
How long has DAFNA Capital Management LLC held RNA?
DAFNA Capital Management LLC has disclosed RNA holdings in 2 of the last 2 reported quarters, going back to Q2 2026.
What is DAFNA Capital Management LLC's current position in RNA?
As of Q3 2026, DAFNA Capital Management LLC holds 300.08K shares of RNA (ATRIUM THERAPEUTICS INC), valued at $2.48M, representing 0.53% of its reported portfolio and ranking #38.
Has DAFNA Capital Management LLC been buying or selling RNA?
In the latest 13F filing (Q3 2026), DAFNA Capital Management LLC increased its position in RNA. The position peaked in Q3 2026 at 300.08K shares.
Which other funds hold RNA?
Other major institutional holders of RNA include Sessa Capital IM, L.P., O'Connor Alternative Investments LLC, Bracebridge Capital, LLC, among 79 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.